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INTRODUCTION 
 
Today the prevalence of obesity is increasing worldwide, leading to 
numerous complications and co-morbidities. In the majority of cases, there is 
a disturbance between the balance of energy input and output, resulting in 
significantly increased body fat mass. Generally speaking, the higher body 
mass index (BMI) is associated with greater health risk compared to normal 
weight individuals. It increases the risk of cardiovascular diseases, 
hypertension, type 2 diabetes mellitus, lipid abnormalities and cancers. As a 
result, a higher BMI means a higher mortality rate. In our studies, we focused 
on the role of cardiovascular risk associated to obesity and overweight, 
including increased oxidative stress, impaired vascular function, and modified 
gastrointestinal hormonal regulation. 
The relationship between obesity, inflammation, oxidative stress and 
atherosclerosis has been in the center of attention for many years. The 
development of atherosclerosis is a complex process in which oxidative 
processes play an important role. Various inflammatory processes induce 
neutrophil cell migration to the vascular wall and production of the 
myeloperoxidase (MPO) enzyme, which is involved in the host defense against 
bacteria via the production of reactive oxygen radicals. However, it also 
promotes oxidative low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) formation, thus reduces the amount of functional HDL 
particles. The oxidation of LDL particles enhances LDL recruitment by the 
scavenger receptor (SR) of the vascular macrophages, thus promotes foam cell 
formation. MPO damages the activity of HDL-bound antioxidant human 
paraoxonase-1 (PON1) enzyme by chlorination and carbamylation of the 
protein. In many clinical studies, MPO activity and protein synthesis proved 
to be an independent risk factor for atherosclerosis. By contrast, PON1 bound 
to the HDL surface and protects it against LDL oxidation, thus inhibits the 
atherogenesis, therefore, PON1 is atheroprotective. Decreased PON1 activity 
has been observed in a number of disorders in which the risk of atherosclerosis 
is increased. 
To date, these vascular biomarkers have been studied mainly in 
patients on statin or statin-ezetimibe treatment; however, it is well known that 
lipid lowering agents are able to modify their serum levels significantly. Thus, 
the aim of the present study was to determine the changes in CD40 ligand 
(sCD40L), asymmetric dimethyl arginine (ADMA), soluble intercellular 
adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-
1 (sVCAM-1) levels, in MPO concentrations as well as in PON1 activity; and 
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to evaluate their relationship with vascular complications and their correlation 
in untreated hyperlipidemic patients. 
 The gastrointestinal tract produces a number of hormone-like proteins 
that regulate the motility of the gastrointestinal tract, thereby affecting the 
appetite, the function of the liver and pancreas. Moreover, they also affect 
several inflammatory and oxidative processes. Obestatin is an energy balance 
regulator peptide hormone associated to ghrelin, participating in the energy 
metabolism by reducing dietary intake and body weight. Furthermore, it has a 
beneficial effect on the function of the cardiovascular system. We investigated 
the possible associations between the concentration of obestatin and the 
function of the HDL particle characterized by HDL-linked anti- and 
proatherogenic enzymes: PON1 and MPO. 
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OBJECTIVES 
 
Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers 
in overweight patients with newly diagnosed untreated hyperlipidaemia: 
 
1. Our aim was to examine serum lipid levels. 
2. To determine paraoxonase and arylesterase activity of antioxidant HDL-
associated PON1 enzyme, and to determine the level of prooxidant MPO. 
3. To measure serum levels of vascular biomarkers including sICAM-1, 
sVCAM-1, ADMA and sCD40L. 
4. To investigate the correlations between PON1 activity and MPO level and 
serum sICAM-1, sVCAM-1, ADMA and sCD40L levels. 
 
 
Serum obestatin level strongly correlates with lipoprotein subfractions in 
nondiabetic obese patients: 
 
5. Our aim was to examine serum lipid levels. 
6. To determine LDL and HDL subfractions. 
7. To measure the level of serum obestatin. 
8. We also investigated the HDL-associated anti- and pro-atherogenic enzymes: 
human paraoxonase-1 (PON1) and myeloperoxidase (MPO). 
9. We also aimed to investigate the correlations between the level of serum 
obestatin and lipid fractions and subfractions. 
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PATIENTS AND METHODS 
 
Enrollment of overweight, hyperlipidemic patients with and without 
vascular complications 
 
The study was carried out in accordance with the Declaration of 
Helsinki of World Medical Association and was previously approved by local 
and regional ethics committees. All investigated subjects gave their written 
informed consent to participate in the study. We enrolled 32 healthy subjects 
as a control group and 167 patient with newly diagnosed Fredrickson type IIa 
and IIb hyperlipidaemia that were referred to our obesity outpatient clinic. 
Physical examination and carotid ultrasound were performed regularly. Other 
imaging techniques (Doppler ultrasound and computer tomography) were 
performed in case of complaints or abnormal physical and electrocardiography 
(ECG) examinations. We examined the presence of hypertension, type 2 
diabetes mellitus, and smoking habits in all patients. Hypertension was defined 
as continuous use of antihypertensive drugs or systolic blood pressure ≥ 140 
mmHg, diastolic BP ≥ 90 mmHg. Type 2 diabetes mellitus was diagnosed by 
recurrent use of antidiabetic drugs or insulin or a fasting blood glucose level 
of  ≥ 7 mmol/L. Smoking status was defined as previous (in the past 10 years, 
lasting longer than six months) and currently smoking. Overweight was 
defined according to the subjects’ body mass index (BMI: 25 kg/m2 – 29.99 
kg/m2). Physical examination and carotid ultrasound were performed 
regularly. Other imaging techniques (Doppler ultrasound and computer 
tomography) were performed in case of complains or abnormal physical and 
electrocardiography (ECG) examinations. Study subjects were divided into 
two gender-matched subgroups as (i) patients with pre-existing vascular 
complications and (ii) patients without vascular complications. Vascular 
complications were defined as ischemic heart disease (myocardial infarction 
or coronary sclerosis), ischemic cerebrovascular disease (ischemic stroke, 
transient ischemic attack, carotid artery stenosis/occlusion), and peripheral 
arterial disease. Vascular complications were established by patient history or 
upon the results of imaging techniques. Study subjects were assigned to the 
“patients with vascular complications” group, if at least one complication 
occurred. At the time of the enrolment, patients were free of acute complains. 
Exclusion criteria included previous and ongoing lipid lowering therapy, 
autoimmune disease, chronic inflammatory conditions, and active liver or 
endocrine disease including type 1 diabetes mellitus, malignancy, and end-
stage kidney failure. 
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Enrollment of non-diabetic obese (NDO) patients 
 
We enrolled fifty non-diabetic obese patients that were referred to our 
obesity outpatient clinic at Department of Internal Medicine, Faculty of 
Medicine, University of Debrecen, Hungary, and thirty-two healthy volunteers 
matched in sex and age. All participants provided written informed consent. 
The study protocol was approved by the Ethical Committee of University of 
Debrecen and the study was carried out in accordance with the Declaration of 
Helsinki. Obesity was defined as BMI ≥ 30 kg/m2. Participants with active 
liver or endocrine disease (including any types of diabetes mellitus), 
cardiovascular disease, renal impairment or malignancy were excluded. 
Further exclusion criteria were pregnancy, lactation, current smoking, and 
alcoholism or drug dependence. Neither obese subjects nor lean healthy 
controls were taking lipid lowering, hyperglycemic, anti-inflammatory, 
antithrombotic medications or dietary supplements. None of participants were 
on antihypertensive treatment with exception of ten obese patients, who were 
on diuretics (indapamide) because of mild hypertension. 
 
Sample collection and laboratory measurements 
 
All venous blood samples were collected after 12-h of fasting. The 
routine laboratory parameters including fasting glucose, fructose amine, high 
sensitive C-reactive protein (hsCRP), total-cholesterol, triglyceride, HDL-C, 
LDL-C, apolipoprotein A1 (apoA1), apolipoprotein B (apoB) and 
lipoprotein(a) levels were determined from fresh sera with Cobas c501 
analyzer (Roche Ltd., Mannheim, Germany) according to the manufacturer’s 
instruction. To check non-diabetic status in study participants, we applied a 
routine 75 g oral glucose tolerance test (OGTT) after an overnight fast. At the 
same time, hemoglobin A1c (HbA1c) and fasting insulin were also performed 
according to the standard laboratory techniques. Homeostasis model 
assessment – insulin resistance (HOMA-IR) was calculated with the formula 
of Matthews et al. Sera were kept frozen at -70 °C for subsequent lipoprotein 
subfraction analysis and for enzyme-linked immunosorbent assay (ELISA) 
measurements. 
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Paraoxonase-1 activities 
 
PON1 paraoxonase activity was analyzed on a microtiter plate by a 
kinetic, semi-automated method using paraoxon (O,O-diethyl-O-p-
nitrophenyl-phosphate, Sigma Aldrich) as a substrate. Enzyme activity was 
calculated using the molar extinction coefficient 17600 M- 1 cm-1. The PON1 
paraoxonase activity is expressed as units per liter of serum, where 1 unit 
equals 1 μmol of substrate hydrolyzed per minute. PON1 arylesterase activity 
was assayed with a phenylacetate substrate (Sigma Aldrich) and the hydrolysis 
of phenylacetate was monitored at 270 nm. Enzyme activity was calculated 
using the molar extinction coefficient 1,310 M-1cm-1. Activity of PON1 
arylesterase is expressed in U/mL; 1 U is defined as 1 μmol phenyl acetate 
hydrolyzed per minute. 
Finally, PON1 phenotype was calculated by the dual substrate 
method. The genetic polymorphism at codon 192 QR is responsible for the 
presence of two isotypes: A (low activity) and B (high activity). The ratio of 
the hydrolysis of paraoxon in the presence of 1 mol/l NaCl (salt-stimulated 
paraoxonase) to the hydrolysis of phenyl acetate was used to assign individuals 
to one of the three possible PON1 phenotypes: AA (low activity), AB 
(intermediate activity), and BB (high activity). Cut-off values between 
phenotypes were as follows: ratio below 3.0 for AA, ratio between 3.0 and 7.0 
for AB, and ratio over 7.0 for BB phenotype. 
 
ADMA, sCD40L, MPO, sICAM, sVCAM, oxLDL and obestatin enzyme-
linked immunosorbent assays 
 
Serum ADMA concentrations were measured by commercially 
available competitive enzyme-linked immunosorbent assay (ELISA) kit (DLD 
Diagnostika GmbH, Hamburg, Germany). Serum concentrations of sCD40L, 
MPO, sVCAM-1, and sICAM-1 were measured by a commercially available 
sandwich ELISA kit (R&D Systems Europe Ltd., Abington, England). Serum 
concentrations of oxidized LDL (oxLDL) were detected by a commercially 
available solid phase two-site enzyme immunoassay (ELISA) kit (Mercodia 
AB, Sweden). Plasma human obestatin was determined by EIA kit 
(Yanaihara Institute Inc., Shizuoka, Japan). 
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Lipoprotein subfraction analyses 
 
HDL and LDL subfractions were detected by an electrophoretic 
method on polyacrylamide gel with the Lipoprint System (Quantimetrix Corp., 
CA, USA) according to the manufacturer’s instructions. Seven LDL 
subfractions are separated from each other during the determination of the LDL 
subfractions and subdivided into HDL subfractions there are ten HDL 
subfractions. In between, up to seven LDL subfractions were distributed.  
Proportion of large LDL (large LDL %) was defined as the sum of the 
percentage of LDL1 and LDL2, whereas proportion of small LDL (small-dense 
LDL %) was defined as the sum of LDL3-LDL7. Cholesterol concentrations 
of LDL subfractions were determined by multiplying the relative AUC of 
subfractions by total cholesterol concentration of the sample. Calculated total 
LDL-C is comprised of the sum of the cholesterol in Midbands C through A 
and LDL subfractions (LDL1- LDL7); and correlates strongly with the directly 
measured LDL-C Ten HDL subfractions were differentiated between 
VLDL+LDL and albumin peaks, and were grouped into three major classes: 
large (from HDL1 to HDL3), intermediate (from HDL4 to HDL7) and small 
(HDL8 to HDL10) HDL subfractions. Cholesterol concentrations of the HDL 
particle subsets were calculated with Lipoware software (Quantimetrix Corp., 
CA, USA) by multiplying the total HDL-C concentration of the samples by the 
relative area under the curve (AUC) of the subfraction bands.  
 
Statistical methods 
 
Statistical analysis was performed by STATISTICA version 8.0 (Statsoft Inc., 
Tulsa, OK, USA). The normality of data distribution was tested by 
Kolmogorov-Smirnov test. Data were presented by descriptive analysis 
(means ±SD in case of normal distribution, or medians [lower quartile – upper 
quartile] in the case of non-normal distribution). Comparisons between groups 
were performed by Student’s unpaired t-test in case of normally distributed 
variables and by Mann-Whitney U-test in case of variables with non-normal 
distribution. Correlations between continuous variables were assessed by 
linear regression analysis using Pearson’s test. Since the distribution of some 
variables of interest became normal upon base-10 logarithm transformation, 
we used the log values for correlation analyses. Multiple regression analysis 
was performed to determine which variables best predicted obestatin 
concentrations. Results were considered to be significant at the level of p < 
0.05. 
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RESULTS 
 
Investigation of serum paraoxonase activity and myeloperoxidase level 
correlation with lipid levels and certain vascular markers in untreated 
hyperlipidemic patients 
 
We found significantly higher glucose, HbA1C, total cholesterol, 
LDL-C, triglyceride, apolipoprotein B, CRP, MPO, sCD40L, sVCAM, 
sICAM, and oxLDL levels in patients compared to the healthy subjects. 
Significantly higher total cholesterol, LDL-C, triglyceride, lipoprotein(a), 
CRP, and uric acid levels were found in patients with vascular complications 
compared to those without any abnormalities. Serum glucose and HbA1C 
levels were also significantly higher in patients with vascular complications, 
although  these parameters remained in the normal range. Mean age of patients 
with vascular complications was significantly higher as well compared to 
patients without vascular complications. Furthermore, concentrations of 
ADMA, sCD40L, sICAM-1, and MPO were significantly higher in patients 
with vascular complications. We could not find significant differences in PON1 
paraoxonase and arylesterase activities or in oxLDL and sVCAM-1 levels 
between the two study groups. Significant negative correlations were detected 
between PON1 arylesterase activities and the concentrations of sCD40L (p = 
0.0262), ADMA (p = 0.0012), and sICAM-1 (p = 0.0398), respectively, in the 
whole study group. We observed significant positive correlations between the 
concentrations of MPO and sCD40L (p < 0.0001), ADMA (p < 0.0001), and 
sICAM-1 levels (p = 0.0282), respectively, in all study participants. After 
separately analyzing these associations in the subgroups, all correlations 
remained significant only in patients without vascular complications. To test 
whether the associations detected in univariate analyses were independent of 
other laboratory parameters, we carried out multiple regression analysis with 
MPO levels as the dependent variable. The model included sCD40L, sICAM-
1, ADMA, and HDL-C levels as well as PON1 arylesterase activity. All the 
other clinical and laboratory parameters including age, BMI, and waist 
circumference did not show any significant correlations with MPO 
concentrations, and were therefore not included. As our results showed, MPO 
concentration turned out to be best predicted by sCD40L and ADMA levels in 
the whole study population (sCD40L: ß = 0.338; p = 0.0001 and ADMA: ß = 
0.381; p = 0.0001, respectively) and in patients without cardiovascular 
complications (sCD40L: ß = 0.319; p < 0.0001 and ADMA: ß = 0.440; 
p < 0.0001, respectively). However, in patients with vascular complications 
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only PON1 arylesterase activity predicted MPO levels independently and 
negatively (ß = -0.410; p = 0.005). 
 
The correlation of serum obestatin levels with lipid parameters, lipid 
subfractions, MPO and paraoxonase-1 activity in non-diabetic (NDO) 
individuals 
 
The NDO patients had extremely high BMI and slightly elevated 
hsCRP level compared to lean individuals. Although, there were several other 
differences in the laboratory parameters in NDO patients compared to lean 
controls, these data were remained in the physiological range. Plasma 
triglyceride and lipoprotein(a) concentrations were found significantly higher, 
while the levels of HDLC and apoAI were significantly lower in the obese 
group compared to normal weight controls. HbA1C level was significantly 
higher in the obese individuals compared to controls. Fasting glucose was in 
normal range in both groups and the blood glucose levels at 120 min of OGTT 
were not elevated in the obese group. On the basis of these laboratory 
parameters the obese patients involved in this study have neither diabetes nor 
impaired glucose tolerance. Significantly higher very low-density lipoprotein 
(VLDL), large LDL, small LDL and small HDL levels, while significantly 
lower intermediate density lipoprotein (IDL), mean LDL size, large HDL and 
intermediate HDL levels were found in NDO patients compared to control 
population. Serum level of obestatin was significantly lower in NDO patients 
compared to controls (3.01 ± 0.5 vs. 3.29 ± 0.6 μg/ml, p < 0.05). We found 
significant negative correlations between obestatin levels and BMI (r = − 0.33; 
p < 0.001), serum glucose levels (r = − 0.27, p < 0.05), HbA1c (r = − 0.38; p 
< 0.001) and insulin (r = − 0.34; p < 0.05). Significant positive correlation was 
found between obestatin level and the levels of ApoA1 (r = 0.25; p < 0.05), the 
ratio in % of large HDL subfractions (r = 0.23; p < 0.05) and the level of large 
HDL subfractions (0.24; p < 0.05). Small HDL subfraction ratio in % showed 
negative, but non-significant correlation with obestatin level (− 0.21; p = 0.06), 
while small HDL level did not show any correlation with obestatin. We 
detected significant positive correlation between obestatin level and mean LDL 
size (r = 0.25; p < 0.05). Significant negative correlations were found between 
obestatin and ratio of VLDL in % (r = − 0.32; p < 0.01) and VLDL level (r = 
− 0.21; p = 0.05), while there were significant positive correlations between 
obestatin and ratio of IDL in % (r = 0.25; p < 0.05) and IDL level (r = 0.23; p 
< 0.05). Increased oxLDL and MPO levels were found in NDO patients 
compared to control population. PON1 paraoxonase and arylesterase acivities 
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did not differ significantly between patients and controls. We could not find 
any significant correlations between obestatin and the levels of MPO and 
PON1 paraoxonase and arylesterase activities. In multiple regression analysis 
obestatin was predicted only by VLDL level. 
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SUMMARY OF THE RESULTS 
 
In untreated, overweight patients with Fredrickson IIa and IIb 
hyperlipidemia and in healthy controls: 
 
1. Significantly higher total cholesterol, LDL-C, triglyceride, ApoB, Lp (a) and 
oxLDL levels were found in dyslipidemic patients compared to control 
populations. In patients with vascular disease, except for ApoB, the same 
parameters were significantly higher than those with non-vascular disease. 
2. Serum paraoxonase and arylesterase activities of the HDL-associated 
antioxidant PON1 enzyme were not significantly different in the patient and 
control population. Nor when compared to a patient group with or without 
vascular disease. 
3. The prooxidant MPO level was significantly higher in patients compared to 
controls, respectively. 
4. Serum levels of sICAM-1, sVCAM-1 and sCD40L were significantly higher 
in patients compared to controls. Significantly higher levels of ADMA, 
sCD40L and sICAM-1 were measured in patients with vascular disease 
compared to patients with non-vascular disease. 
5. The arylesterase activity of PON1 showed significant negative correlation with 
serum sICAM-1, ADMA and sCD40L levels in dyslipidemic patients. 
6. MPO level showed a significant positive correlation with serum sICAM-1, 
ADMA and sCD40L levels. In multiple regression analysis, the sCD40L and 
ADMA levels were independent predictors of the MPO level for the entire 
patient population. 
 
 
In non-diabetic obese patients and healthy controls: 
 
7. Significantly higher levels of triglycerides and Lp (a) and significantly lower 
HDL-C and ApoA1 levels were observed in obese patients compared to the 
control population, but these values were within the normal reference range. 
OxLDL levels were significantly higher in obese patients compared to 
controls. 
8. We found that VLDL, large LDL, small LDL and small HDL subfractions were 
significantly higher in obese patients compared to healthy controls. The 
average LDL size was significantly lower in patients compared to controls. 
9. Significantly lower serum levels of obestatin were found in obese patients 
compared to control populations. 
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10. The antioxidant PON1 paraoxonase and arylesterase activities showed no 
significant differences in the two study groups. 
11. The prooxidant MPO level was significantly higher in obese patients compared 
to controls. 
12. Serum levels of obestatin showed significant negative correlation with BMI, 
HbA1c, serum glucose and insulin, but not correlated with PON1 activities and 
MPO level. 
13. Serum level of obestatin was positively correlated with the ApoA1 level and 
the amount and ratio of the large HDL subfraction, the level and the ratio of 
IDL subfraction and the average LDL size. Negative correlation was found 
with the amount and ratio of VLDL subfraction. Based on the result of the 
multiple regression analysis, VLDL proved to be the only significant negative 
predictor for obestatin levels. 
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DISCUSSION 
 
Obesity and overweight, as well as increased atherosclerosis resulting 
arterial complications, are becoming more and more common worldwide, so 
these researches are also of paramount importance to better understand the 
association between weight gain and atherosclerosis. 
To the best of our knowledge, the significant negative associations 
between sCD40L, ADMA, sICAM-1 levels, and PON1 arylesterase activity, 
as well as the significant positive correlations between sCD40L, ADMA, 
sICAM-1, and MPO levels in untreated hyperlipidemic patients are novel 
results. Multiple regression analysis proved that sCD40L and ADMA levels 
were independent predictors of MPO levels in the whole study population and 
in patients without vascular complications, while in patients with vascular 
complications, only PON1 arylesterase activity was a negative predictor of 
MPO concentration. 
Previous studies proved that both statins and ezetimibe could alter the 
concentrations of these biomarkers, including significant alterations in the 
plasma levels of lipoprotein(a) and MPO. Furthermore, circulating 
concentrations of CRP and sICAM-1 were found to be decreased in patients 
receiving both simvastatin and ezetimibe. Therefore, associations between 
vascular biomarkers might be different in untreated patients and enrolment of 
treatment-naive hyperlipidaemic patients could provide additional valuable 
information about their vascular effects. Polymorphonuclear leukocytes are 
potential sources of superoxide radicals and inflammatory mediators. Their 
priming contributes to chronic systemic oxidative stress and low-grade 
inflammation leading to endothelial dysfunction, accelerated atherosclerosis, 
and increased prevalence of cardiovascular complications. Indeed, a decrease 
in polymorphonuclear leukocyte-MPO levels with increased levels of serum 
MPO were found in hyperlipidemic patients. Based on these findings, the 
positive correlations between the concentration of MPO and sCD40L, ADMA, 
sICAM-1 levels may highlight the role of polymorphonuclear leukocytes in 
the atherosclerotic process. Additionally, ADMA was found to impair nitric 
oxide synthesis of polymorphonuclear leukocytes, resulting in increased 
leukocyte adhesion to endothelial cells, superoxide generation, and MPO 
release. The significant association between MPO and ADMA levels may 
prove the ADMA/MPO interaction concept. 
A previous study has provided strong evidence that low PON1 activity 
predicts future risk for CVD.  Still, the exact endogenous substrates and the 
mechanisms with which PON1 protects against atherosclerosis are still 
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unknown. The activity of the enzyme is usually measured with paraoxon as a 
substrate (paraoxonase activity) to characterize its antioxidant capacity; and 
with phenyl acetate (arylesterase activity) which is considered to correlate with 
its serum level. It has been proposed that paraoxonase proteins including PON1 
primarily possess lactonase activity. Noteworthy, 5-hydroxyicosatetraenoic 
acid (5-HETE) lactone is metabolized by PON1, possibly resulting in a 
modulation of the local anti-inflammatory response. Since arylesterase activity 
correlates with the enzyme’s lactonase activity, one may hypothesize that 
negative correlations between PON1 arylesterase activity and ADMA, 
sCD40L, and sICAM-1 levels may reflect the anti-inflammatory effect of 
PON1. Interestingly, PON1 arylesterase activity was found to be an 
independent predictor of MPO levels only in patients with vascular 
complications, while this association disappeared in patients without vascular 
complications. The favorable properties of PON1 could contribute 
considerably to the capacity of HDL to inhibit atherosclerosis. However, 
systemic and vascular inflammation have been suspected to convert HDL to a 
dysfunctional form with impaired antiatherogenic effects. Furthermore, an 
elegant study proved the existence of an HDL-MPO-PON1 ternary complex, 
in which each partner functions as a reciprocal modulator of the other’s 
activity, influencing oxidant stress and lipid peroxidation during inflammation. 
Our previous study on the same patient population also underlines the 
importance of this reciprocal inhibition. 
Overall, our results and literature data suggest that increased 
production of MPO is due to activation of neutrophilic cells in untreated 
hyperlipidemic patients, resulting in increased MPO activity and consequently 
reactive free radical production. Due to the decreased PON1 activity and 
increased serum MPO level antioxidant and anti-inflammatory efficacy of the 
HDL particle is reduced. Increased oxidative stress leading to increased cell 
surface expression of the adhesion molecules, including sICAM-1. In parallel, 
increased oxidative stress is induced in the activation of platelets and their 
enhanced sCD40L production. On the surface of platelets, cleavage of CD40L 
is performed by matrix metalloproteases is produced in large amounts during 
arterial inflammation. SCD40L binds to the CD40 receptor on the surface of 
endothelial cells, which partly reduces nitric oxide production through 
inhibition of nitric oxide synthase, further enhances vascular matrix 
metalloprotease production and cell surface expression of adhesion molecules. 
Increased level of sCD40L also results in the activation of further 
inflammatory cells. Thus, these processes reinforce the formation of vascular 
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inflammation, which is one of the first steps in the atherogenesis and the most 
important cause of impaired endothelial function. 
 
The relationship between the function of the digestive tract and the 
regulation of lipid metabolism can be considered as plausible, still, the related 
literature data is rather incomplete. However, in the last decades number of 
proteins with hormone-like effects have been identified which are produced by 
the digestive tract. One of them is obestatin. 
Obestatin acts as an anorectic hormone that decreases food intake, 
slowed gastrointestinal motility and therefore reduces weight gain. Previous 
studies in humans showed significantly lower plasma obestatin levels in 
diabetic or non-diabetic obese subjects compared to lean controls but failed to 
assess diabetes mellitus or impaired glucose tolerance status. We found similar 
results in our obese subjects without diabetes. The exact role of obestatin in 
regulation of lipoprotein levels is not completely clarified. To the best of our 
knowledge, correlations between obestatin levels and lipoprotein subfractions 
have not been investigated previously. 
We found a significant positive correlation between obestatin level 
and the levels of ApoA1 and large HDL subfractions, which may indicate a 
possible connection between the abnormal gastrointestinal response and 
decreased hepatic ApoA1 expression in obesity. Furthermore, serum VLDL 
ratio and level negatively correlated with obestatin, which may be explained 
by the previously described association between the serum level of obestatin 
and carbohydrate metabolism, since insulin resistance and the higher level of 
serum glucose result in increased hepatic free fatty acid production leading to 
elevated VLDL level. Moreover, in multiple regression analysis VLDL level 
was the only independent predictor of obestatin level. The negative VLDL 
correlation may also explains the positive correlation of large HDL subfraction 
with obestatin levels, which was on the border of significance (p = 0.06) in 
multiple regression analysis. Increased transport of triglyceride from VLDL to 
HDL and cholesterol-esther from HDL to VLDL by cholesterol-esther transfer 
protein lead to the formation of smaller and denser HDL particles with 
enhanced degradation and lower half lifespan, which results in low total HDL-
C levels and a shift towards smaller HDL subfractions. We also investigated 
the activity of human paraoxonase-1, an antioxidant enzyme mainly associated 
with smaller HDL particles containing apolipoprotein J (clusterin). Although 
both paraoxonase and arylesterase activities of the enzyme tended to be lower 
in obese subjects, there were no significant differences in enzyme activities 
18 
 
between the two study groups, despite the shift towards the smaller HDL 
subfractions. 
Furthermore, we found no significant correlation between obestatin 
levels and PON1 enzyme activity. The level of another HDL associated, 
proatherogenic enzyme: MPO was also investigated. In line with some 
previous studies we found significantly higher myeloperoxidase level in obese 
subjects compared to lean controls. Previous data showed that MPO, PON1, 
and HDL may bind to each other, forming a ternary complex, wherein PON1 
partially inhibits MPO activity and MPO inactivates PON1 influencing 
endogenous oxidative stress and lipid peroxidation during inflammation. In our 
previous study PON1 arylesterase activity was found to be an independent 
predictor of MPO levels in overweight hyperlipidemic, lipid-lowering therapy 
naive patients. In the nondiabetic obese group there were no significant 
correlations either between paraoxonase activity and MPO level or between 
obestatin and MPO level. 
A previous study showed obestatin increased oxLDL binding to 
macrophages. Although, oxLDL level was significantly higher in obese 
patients, we could not find significant correlation between the levels of oxLDL 
and obestatin. 
We concluded that decreased level of obestatin may contribute to the 
development of metabolic syndrome and altered lipoprotein metabolism in 
obese patients even without disturbed insulin sensitivity. However, obestatin 
level does not correlate to HDL function markers including PON1 and MPO 
and has no effect on the level of oxidized LDL. Based on our data, 
measurement of obestatin level in obesity may contribute to understand the 
interplay between gastrointestinal hormone secretion and metabolic alterations 
in obesity. 
In our work, we provided new data about unfavorable effects of 
overweight and obesity by determining the quantitative and qualitative 
parameters of lipid metabolism. We have verified their correlations with the 
vascular biomarkers and the level of hormone protein produced by the 
digestive system, which can help to better understand the causes of increased 
cardiovascular risk associated to obesity and overweight. Thereby enabling 
new therapeutic pathways to be explored and widening future medication and 
non-medication treatment. 
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SUMMARY 
 
Obesity is one of the leading causes of morbidity and mortality in the 
world and its prevalence has risen at an alarming rate over the past two 
decades. Numerous studies have shown a clear relationship between obesity 
and risk of developing cardiovascular disease (CVD). Dyslipidemia is 
frequently associated to obesity and overweight and a well-known risk factor 
of CVD. In dyslipidemia, the high-density lipoprotein (HDL) function is 
impaired characterized by increased levels of myeloperoxidase (MPO) and 
decreased paraoxonase-1 (PON1) activity, however, their relationships with 
other atherosclerotic biomarkers have not been completely clarified. Obestatin 
is a recently identified anorexigenic gut hormone. Its plasma concentrations 
were negatively correlated with body mass index (BMI) and insulin resistance 
index in obesity. Accumulating evidence supports its positive actions on both 
lipid metabolism and cardiovascular function. To date, level of obestatin and 
its correlations to the lipid subfractions in non-diabetic obese (NDO) patients 
have not been investigated. 
Therefore, serum concentrations of lipid and inflammatory 
parameters, MPO levels and PON1 activities were investigated in 167 
untreated hyperlipidemic overweight patients with and without vascular 
complications and in 32 healthy controls. Additionally, levels of CD40 ligand 
(sCD40L) and asymmetric dimethyl arginine (ADMA), soluble intercellular 
adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 
and oxidized LDL (oxLDL) were determined. Furthermore, we aimed to 
measure the level of serum obestatin and evaluate its correlations to the lipid 
fractions and subfractions in non-diabetic obese (NDO) patients and in 
controls. We also investigated the possible associations between the 
concentration of obestatin and the HDL function characterized by PON1 
acitivities and MPO levels. 
In dyslipidemic overweight patients we found significantly higher 
glucose, hemoglobin A1c (HbA1c), total cholesterol, low-density lipoprotein 
(LDL)-cholesterol, triglyceride, lipoprotein(a), apolipoprotein B, C-reactive 
protein (CRP), MPO, sCD40L, sVCAM-1, sICAM-1 and oxLDL levels 
compared to the healthy subjects.  We found elevated CRP, ADMA, sCD40L, 
sICAM-1 concentrations and higher MPO levels in patients with vascular 
complications compared to those without. PON1 arylesterase activity 
correlated negatively with sCD40L, ADMA and sICAM-1 levels, respectively. 
MPO concentrations showed positive correlations with sCD40L, ADMA, 
sICAM-1 levels, respectively. MPO concentration turned out to be best 
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predicted by sCD40L and ADMA levels in the whole study population and in 
patients without cardiovascular complications. However, in patients with 
vascular complications, only PON1 arylesterase activity was an independent 
(and negative) predictor of MPO level. 
In NDO patients the serum level of obestatin was significantly lower 
compared to controls. We found significant negative correlations between the 
level of obestatin and BMI, level of serum glucose, HbA1c and insulin. 
Significant positive correlation was found between obestatin level and the 
levels of apolipoprotein A1, large HDL subfraction ratio and level, 
intermediate-density lipoprotein and mean LDL size. Serum very low-density 
lipoprotein (VLDL) ratio and level negatively correlated with obestatin. In 
multiple regression analysis obestatin was predicted only by VLDL level. 
We conclude that in overweight dyslipidemic patients PON1 activity and MPO 
level correlate strongly with the vascular biomarkers, highlighting the 
importance of the HDL-associated pro- and antioxidant enzymes in the 
development of endothelial dysfunction and atherogenesis. Based on our data, 
measurement of obestatin level in obesity may contribute to understand the 
interplay between gastrointestinal hormone secretion and metabolic alterations 
in obesity. 
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